Stephens Forecasts Strong Price Appreciation for Health Catalyst (NASDAQ:HCAT) Stock

Health Catalyst (NASDAQ:HCAT) had its target price boosted by research analysts at Stephens from $7.00 to $9.00 in a report released on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Stephens’ target price would suggest a potential upside of 3.93% from the stock’s current price.

Several other research analysts also recently weighed in on the stock. JPMorgan Chase & Co. increased their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Royal Bank of Canada boosted their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Piper Sandler decreased their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Evercore ISI upped their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Citigroup boosted their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $11.71.

Health Catalyst Stock Performance

Shares of HCAT opened at $8.66 on Thursday. The firm has a market capitalization of $526.96 million, a P/E ratio of -6.41 and a beta of 1.32. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a one year low of $5.42 and a one year high of $11.41. The business has a fifty day moving average of $8.13 and a 200 day moving average of $7.20.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Health Catalyst will post -0.35 EPS for the current year.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the transaction, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,068 shares of company stock worth $257,555 over the last three months. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC grew its holdings in shares of Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares during the last quarter. Impax Asset Management Group plc lifted its position in Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after acquiring an additional 360,201 shares during the period. Millennium Management LLC grew its stake in Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after purchasing an additional 1,184,131 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after purchasing an additional 25,000 shares during the period. Finally, Daventry Group LP raised its stake in shares of Health Catalyst by 3.9% in the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after purchasing an additional 84,178 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.